Individuals are given one vaccination at the 4 years National Immunisation Program Schedule point:

  • Infanrix IPV or Quadracel protects against diphtheria, tetanus, whooping cough and polio

AusVaxSafety has been conducting surveillance of the vaccine given at the 4 years Schedule point on a continuous basis since 2019. The analysis has remained constant over this time and not identified any safety concerns.

The latest medical attendance rate for the 4 years Schedule point is below and will be updated on a quarterly basis.


In April 2022, the vaccine safety survey used for active surveillance of vaccines on the National Immunisation Program was updated to replicate the vaccine safety survey used for COVID-19 and seasonal influenza vaccine surveillance to allow for better comparison across all vaccines monitored. Data displayed on this page show analysis of the new survey. Reassuringly, data from the new vaccine safety survey are comparable to the rates reported in the previous survey below.

More detailed safety data from the 4 years Schedule point is available from the 2020 Vaccine Safety in Australia AusVaxSafety Summary Report below.

Click here to download AusVaxSafety data from the 4 years schedule point for 2020

Last updated August 2022